Restricted accessBrief reportFirst published online 2021-6
Severe metabolic acidosis and hyperkalemia after peptide receptor radionuclide therapy. A case report,review of the literature and proposed treatment algorithm
Peptide receptor radionuclide therapy (PRRT) has been increasingly used in the treatment of patients with well-differentiated neuroendocrine neoplasms (WD-NENs), but electrolyte abnormalities during prophylactic aminoacid (AA) infusion can complicate its administration. We describe a case of AA-induced acidosis and hyperkalemia associated with PRRT. We tailored an oral and intravenous sodium bicarbonate regimen for pre-emptive treatment prior to subsequent PRRT session, thereby preventing hospitalization. We provide a relevant review of the literature and our treatment algorithm, that can serve as a point of reference in treatment of this life-threatening complication of PRRT.
DasariAShenCHalperinD, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol2017; 3: 1335–1342.
3.
ImhofABrunnerPMarincekN, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol2011; 29: 2416–2423.
4.
BrabanderTvan der ZwanWATeunissenJJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res2017; 23: 4617.
5.
StrosbergJEl-HaddadGWolinE, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med2017; 376: 125–135.
6.
WernerRABrumbergJDierksA, et al. Paralytic subileus as an adverse effect of amino acid-based nephroprotection in a patient undergoing peptide receptor radionuclide therapy. Clin Nucl Med2015; 40: 263–264.
7.
LapaCWernerRABluemelC, et al. Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy. EJNMMI Res2014; 4: 74.
8.
MaughanNMKimHHaoY, et al. Initial experience and lessons learned with implementing Lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology–based program. Brachytherapy2020; 20: 237–247.
9.
PattisonDASolomonBHicksRJ.A new theranostic paradigm for advanced thyroid cancer. J Nucl Med2016; 57: 1493–1494.
10.
HofmanMSVioletJHicksRJ, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol2018; 19: 825–833.
11.
BehrTMGoldenbergDMBeckerW.Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med1998; 25: 201–212.
12.
VegtEMelisMEekA, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging2011; 38: 623–632.
13.
HammondPJWadeAFGwilliamME, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer1993; 67: 1437–1439.
14.
DePalatisLRFrazierKAChengRC, et al. Lysine reduces renal accumulation of radioactivity associated with injection of the [177Lu]alpha-[2-(4-aminophenyl) ethyl]-1,4,7,10-tetraaza-cyclodecane-1,4,7,10-tetraacetic acid-CC49 Fab radioimmunoconjugate. Cancer Res1995; 55: 5288–5295.
15.
RollemanEJKrenningEPBernardBF, et al. Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging2007; 34: 219–227.
16.
RollemanEJValkemaRde JongM, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging2003; 30: 9–15.
17.
LevinskyNGTysonIMillerRB, et al. The relation between amino acids and potassium in isolated rat muscle. J Clin Invest1962; 41: 480–487.
18.
DickermanHWWalkerWG.Effect of cationic amino acid infusion on potassium metabolism in vivo. Am J Physiol1964; 206: 403–408.
19.
KnochelJP.Complications of total parenteral nutrition. Kidney Int1985; 27: 489–496.
20.
PfobCHEiberMLuppaP, et al. Hyperkalemia in patients treated with endoradiotherapy combined with amino acid infusion is associated with severe metabolic acidosis. EJNMMI Res2018; 8: 17.
21.
LapaCWernerRABluemelC, et al. Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapy. EJNMMI Res2014; 4: 46.
22.
BaroneRPauwelsSDe CampsJ, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant2004; 19: 2275–2281.
23.
HarrisANGrimmPRLeeHW, et al. Mechanism of hyperkalemia-induced metabolic acidosis. J Am Soc Nephrol2018; 29: 1411–1425.
24.
GiovacchiniGNicolasGFreidankH, et al. Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy. Eur J Nucl Med Mol Imaging2011; 38: 1675–1682.
25.
JamarFBaroneRMathieuI, et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging2003; 30: 510–518.
26.
AsbachSSchluermannFRufJ, et al. Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor. Clin Case Rep2018; 6: 197–199.
27.
Ben ReguigaM. Interaction of 177Lu-DOTATATE with pharmaceutical vehicles and peptides. European journal of nuclear medicine and molecular imaging2018; 2018: 3(Suppl 1): PP26.
